China's vast market offers irresistible appeal, and its dynamic innovation capabilities are increasingly driving global progress, according to an executive from ZAP Surgical, a U.S. medical technology company.
The company's Chinese partner, Baheal Medical Group, just inaugurated a high-end pharmaceutical manufacturing base in Langfang City of north China's Hebei Province on Saturday, which will produce the U.S. company's advanced brain tumor radiotherapy systems for global sales.
In an interview with China Global Television Network (CGTN), John Adler, founder and CEO of ZAP Surgical, expressed his confidence in investing in China.
"At first, we were very much attracted by the sheer size of the Chinese market. The number of patients would benefit from the technology we made. But then, as we started looking into what it would mean to manufacture, we realized how much we could lower the cost of goods and lower the cost of our device. And since we want to sell around the world, we were much better positioned to do that with a lower cost of device. Meanwhile, it's undeniable that China is an innovation tiger. It is, I think, crossing a threshold of just following the innovation of other countries, the United States in particular, to being an innovation giant itself. And so throughout all the life sciences, we've seen enormous growth in what China has contributed to the world," he said.
US med-tech firm optimistic about China's market, cooperation
